Clinical Trial · NCT04288518

Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.

Overview

The study should evaluate the biological distribution of 99mTc-1-thio-D-glucose in patients with primary brain tumors and recurrence of brain tumors. The primary objective are: 1. To assess the distribution of 99mTc-1-thio-D-glucose in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of 99mTc-1-thio-D-glucose. 3. To study the safety and tolerability of the drug 99mTc-1-thio-D-glucose after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained SPECT imaging results of brain tumors with the data of magnetic resonance imaging (MRI) and/or positron emission tomography (PET) and immunohistochemical (IHC) studies of postoperative material.

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase

Phase 1/2

Contacts

Vladimr I Chernov (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04288518

Eligibility

Inclusion

Serum creatinine: Within Normal Limits
Platelets: \> 50.0 x 10\^9/L
Bilirubin =\< 2.0 times Upper Limit of Normal
White blood cell count: \> 2.0 x 10\^9/L
Clinical and radiological diagnosis of a benign intracranial lesions.
alanine amino transferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST): =\< 5.0 times Upper Limit of Normal
Clinical and radiological diagnosis of a primary brain tumor or recurrence of a brain tumor with immunohistological verification.
Subject is capable to undergo the diagnostic investigations to be performed in the study
Haemoglobin: \> 80 g/L

Exclusion

Exclusion criteria not yet provided.